BeOne Medicines AG ONC
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.86B | 1.68B | 1.49B | 1.48B | 1.40B |
| Total Other Revenue | 34.76M | 25.28M | 26.11M | 21.73M | 17.27M |
| Total Revenue | 1.89B | 1.71B | 1.51B | 1.50B | 1.41B |
| Cost of Revenue | 216.90M | 174.53M | 167.22M | 142.42M | 196.51M |
| Gross Profit | 1.67B | 1.53B | 1.35B | 1.36B | 1.22B |
| SG&A Expenses | 593.46M | 593.21M | 555.10M | 555.29M | 529.00M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.47B | 1.38B | 1.26B | 1.31B | 1.25B |
| Operating Income | 418.68M | 325.05M | 249.90M | 185.04M | 163.11M |
| Income Before Tax | 410.36M | 312.46M | 259.22M | 149.24M | 147.16M |
| Income Tax Expenses | 25.65M | 75.45M | 31.86M | 82.74M | 22.32M |
| Earnings from Continuing Operations | 384.71M | 237.01M | 227.36M | 66.50M | 124.84M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 384.71M | 237.01M | 227.36M | 66.50M | 124.84M |
| EBIT | 418.68M | 325.05M | 249.90M | 185.04M | 163.11M |
| EBITDA | 456.01M | 363.97M | 289.30M | 219.47M | 198.86M |
| EPS Basic | 43.99 | 27.61 | 26.64 | 7.81 | 14.73 |
| Normalized Basic EPS | 2.26 | 1.73 | 1.46 | 1.07 | 0.91 |
| EPS Diluted | 42.25 | 27.04 | 25.35 | 6.80 | 13.52 |
| Normalized Diluted EPS | 2.19 | 1.67 | 1.40 | 1.03 | 0.88 |
| Average Basic Shares Outstanding | 113.70M | 111.58M | 110.96M | 110.73M | 110.22M |
| Average Diluted Shares Outstanding | 9.02M | 8.91M | 8.91M | 8.88M | 8.81M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |